Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Company Overview - Perspective Therapeutics, Inc. is a radiopharmaceutical development company focused on advanced treatment applications for cancers throughout the body [3] - The company utilizes proprietary technology with the alpha-emitting isotope Pb to deliver targeted radiation specifically to cancer cells [3] - Perspective is developing complementary imaging diagnostics that enhance the personalization of treatment and optimize patient outcomes through a "theranostic" approach [3] Clinical Development - The company's melanoma program (VMT01) and neuroendocrine tumor program (VMT-α-NET) are currently in Phase 1/2a imaging and therapy trials for metastatic melanoma and neuroendocrine tumors at leading academic institutions [4] - Perspective has developed a proprietary Pb generator to secure key isotopes necessary for clinical trials and commercial operations [4] Investor Engagement - Members of the senior leadership team will participate in upcoming investor conferences, including Oppenheimer's 35th Annual Healthcare Life Sciences Conference on February 12, 2025, and B. Riley Securities Precision Oncology & Radiopharma Investor Conference on February 28, 2025 [2]